Fukushima Medical University · Unclassified

Research keywordsメタ疫学・臨床腫瘍学・臨床疫学・老年医学・泌尿器科学

This is a public-data preview. Personalized fit, contact angles, and saved workflows require sign-in.

• Comparison of real-world outcomes between nivolumab plus ipilimumab and lenvatinib plus pembrolizumab or nivolumab plus cabozantinib combination therapies for previously untreated advanced renal cell carcinoma.2025 · Ishihara H, Omae K, Nemoto Y, Mizoguchi S, Katsurayama N, Nakayama T, Fukuda H, Yoshida K, Shimmura H, Hashimoto Y, Iizuka J, Kondo T, Takagi T
• Hesitancy or Straining, That Is the Question: Which Does Question 6 of the International Prostate Symptom Score Represent?2025 · Sekido N, Omae K, Haga N, Kubota Y, Saito M, Sakakibara R, Yoshida M, Mitsui T, Masumori N, Takahashi S
• Prevalence, Impact on Quality of Life, and Predictive Factors of Co-Existent Overactive-Underactive Bladder in Women.2025 · Sekido N, Omae K, Haga N, Kubota Y, Saito M, Sakakibara R, Yoshida M, Mitsui T, Masumori N, Takahashi S
• Long-term real-world outcomes of nivolumab plus ipilimumab for advanced renal cell carcinoma: a minimum of 4-years follow-up study.2025 · Ishihara H, Nishimura K, Nemoto Y, Mizoguchi S, Nakayama T, Fukuda H, Shimmura H, Hashimoto Y, Yoshida K, Iizuka J, Omae K, Kondo T, Takagi T

• 過活動膀胱治療に対する患者価値観に基づくSmallest Worthwhile Difference推定2024 · 2024年10月
• β3アドレナリン受容体作動薬を用いた過活動膀胱治療におけるSmallest Worthwhile Differenceの推定2024 · 2024年2月
• 全県的データベースを利用したCOVID-19の増悪危険因子の経時的な解析2022 · 2022年4月
• 疫学を中心とした学際的アプローチに基づく医学論文査読の実証分析と教育への応用2022 · 2022年4月

• Official profile